open access

Vol 93, No 6 (2022)
Research paper
Published online: 2021-11-29
Get Citation

There is no significant correlation of adenomyosis with benign, premalignant and malignant gynecological pathologies. Retrospective study on 647 specimens

Michail Matalliotakis1, Maria I. Zervou2, Charoula Matalliotaki3, George N. Goulielmos2, Konstantinos Krithinakis3, Georgios Kapetanios1, Ioannis Kalogiannidis1
·
Pubmed: 35072225
·
Ginekol Pol 2022;93(6):467-472.
Affiliations
  1. 3rd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Konstantinoupoleos, Thessaloniki, Greece
  2. Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece
  3. Department of Obstetrics and Gynaecology, Venizeleio and Pananio General Hospital of Heraklion, Heraklion, Greece

open access

Vol 93, No 6 (2022)
ORIGINAL PAPERS Gynecology
Published online: 2021-11-29

Abstract

Objectives: The aim of this study is to identify the prevalence of benign, premalignant and malignant gynecological pathologies in women with adenomyosis who underwent gynecological surgery. Material and methods: The medical records collected between 1985 and 2020 were retrospectively reviewed. The pathology reports were studied from 647 cases where adenomyosis was presented. The estimated prevalence of benign, premalignant and malignant gynecological disorders in the general population was further evaluated. Results: The mean age of women with adenomyosis was 54.1 ± 10.4 years old. Out of 647 patients, in 18.5% of the specimens we detected isolated adenomyosis and in 81.5% of cases a coexistence of one or more gynecological diseases, while in 84 out of 647 patients (13%) there was coexistence of adenomyosis with more than one gynecological condition (benign or malignancy). Among all cases, uterine leiomyomas were observed in 61.3% of patients, followed by endometrial polyps (11.9%), endometriosis (11.6%), endometrial hyperplasia (7.1%), endometrial cancer (3.6%), ovarian (1.4%) and cervical cancer (0.8%) (p < 0.001).Additionally, we found that women with a simultaneous co-existence of adenomyosis, leiomyomas and endometrial polyps or hyperplasia were younger (p < 0.01) in comparison to cases with malignancy. Conclusions: Adenomyosis presents a common benign but often progressing myometrial condition that it is underestimated in clinical practice. Even though some studies suggest a potential association with several gynecological pathologies, we did not confirm a significant difference of adenomyosis prevalence between benign, premalignant and malignant gynecological conditions compared with the general population. Further investigation is required to confirm our results.

Abstract

Objectives: The aim of this study is to identify the prevalence of benign, premalignant and malignant gynecological pathologies in women with adenomyosis who underwent gynecological surgery. Material and methods: The medical records collected between 1985 and 2020 were retrospectively reviewed. The pathology reports were studied from 647 cases where adenomyosis was presented. The estimated prevalence of benign, premalignant and malignant gynecological disorders in the general population was further evaluated. Results: The mean age of women with adenomyosis was 54.1 ± 10.4 years old. Out of 647 patients, in 18.5% of the specimens we detected isolated adenomyosis and in 81.5% of cases a coexistence of one or more gynecological diseases, while in 84 out of 647 patients (13%) there was coexistence of adenomyosis with more than one gynecological condition (benign or malignancy). Among all cases, uterine leiomyomas were observed in 61.3% of patients, followed by endometrial polyps (11.9%), endometriosis (11.6%), endometrial hyperplasia (7.1%), endometrial cancer (3.6%), ovarian (1.4%) and cervical cancer (0.8%) (p < 0.001).Additionally, we found that women with a simultaneous co-existence of adenomyosis, leiomyomas and endometrial polyps or hyperplasia were younger (p < 0.01) in comparison to cases with malignancy. Conclusions: Adenomyosis presents a common benign but often progressing myometrial condition that it is underestimated in clinical practice. Even though some studies suggest a potential association with several gynecological pathologies, we did not confirm a significant difference of adenomyosis prevalence between benign, premalignant and malignant gynecological conditions compared with the general population. Further investigation is required to confirm our results.

Get Citation

Keywords

adenomyosis; endometriosis; benign gynecological diseases; gynecological malignancy

About this article
Title

There is no significant correlation of adenomyosis with benign, premalignant and malignant gynecological pathologies. Retrospective study on 647 specimens

Journal

Ginekologia Polska

Issue

Vol 93, No 6 (2022)

Article type

Research paper

Pages

467-472

Published online

2021-11-29

Page views

4961

Article views/downloads

1044

DOI

10.5603/GP.a2021.0174

Pubmed

35072225

Bibliographic record

Ginekol Pol 2022;93(6):467-472.

Keywords

adenomyosis
endometriosis
benign gynecological diseases
gynecological malignancy

Authors

Michail Matalliotakis
Maria I. Zervou
Charoula Matalliotaki
George N. Goulielmos
Konstantinos Krithinakis
Georgios Kapetanios
Ioannis Kalogiannidis

References (35)
  1. Guo SW. The Pathogenesis of adenomyosis vis-à-vis endometriosis. J Clin Med. 2020; 9(2).
  2. Matalliotakis IM, Kourtis AI, Panidis DK. Adenomyosis. Obstet Gynecol Clin North Am. 2003; 30(1): 63–82, viii.
  3. Vercellini P, Viganò P, Somigliana E, et al. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006; 20(4): 465–477.
  4. Filip G, Balzano A, Cagnacci A. Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. Minerva Ginecol. 2019; 71(3): 177–181.
  5. Munro MG. Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity. Fertil Steril. 2019; 111(4): 629–640.
  6. De Wilde RL, Wallwiener M, Di Spiezio Sardo A, et al. Adenomyosis and myomata: risks, problems, and complications in diagnosis and therapy of adenomyosis and myomata. Biomed Res Int. 2018; 2018: 5952460.
  7. Habiba M, Pluchino N, Petignat P, et al. Adenomyosis and endometrial cancer: literature review. Gynecol Obstet Invest. 2018; 83(4): 313–328.
  8. Gassman WT. Announcements Figo Stages- 1988 Revision. GynecolOncol. 1989; 35: 125–127.
  9. Mahnert N, Morgan D, Campbell D, et al. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol. 2015; 125(2): 397–405.
  10. Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus--revisited. Am J Obstet Gynecol. 1972; 112(5): 583–593.
  11. Mehasseb MK, Panchal R, Taylor AH, et al. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril. 2011; 95(7): 2228–35, 2235.e1.
  12. Inagaki N, Ung L, Otani T, et al. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. Eur J Obstet Gynecol Reprod Biol. 2003; 111(2): 197–203.
  13. Kitawaki J, Obayashi H, Ishihara H, et al. Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod. 2001; 16(1): 51–55.
  14. Shan K, Lian-Fu Z, Hui Du, et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-7, -9 and the risk of endometriosis and adenomyosis in China. Mol Hum Reprod. 2006; 12(1): 35–39.
  15. Inoue S, Hirota Y, Ueno T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019; 10(1): 5785.
  16. Kang S, Li SZ, Wang Na, et al. Association between genetic polymorphisms in fibroblast growth factor (FGF)1 and FGF2 and risk of endometriosis and adenomyosis in Chinese women. Hum Reprod. 2010; 25(7): 1806–1811.
  17. Yeh CC, Su FH, Tzeng CR, et al. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLOS ONE. 2018; 13(3): e0194011.
  18. Taran FA, Wallwiener M, Kabashi D, et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective study in 291 patients. Arch Gynecol Obstet. 2012; 285(6): 1571–1576.
  19. Verit FF, Yucel O. Endometriosis, leiomyoma and adenomyosis: the risk of gynecologic malignancy. Asian Pac J Cancer Prev. 2013; 14(10): 5589–5597.
  20. Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017; 124(10): 1501–1512.
  21. American Association of Gynecologic Laparoscopists. AAGL practice report: practice guidelines for the diagnosis and management of endometrial polyps. J Minim Invasive Gynecol. 2012; 19(1): 3–10.
  22. Sobczuk K, Sobczuk A. New classification system of endometrial hyperplasia WHO 2014 and its clinical implications. Prz Menopauzalny. 2017; 16(3): 107–111.
  23. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017; 6(1): 34–41.
  24. Koike N, Tsunemi T, Uekuri C, et al. Pathogenesis and malignant transformation of adenomyosis (review). Oncol Rep. 2013; 29(3): 861–867.
  25. Kucera E, Hejda V, Dankovcik R, et al. Malignant changes in adenomyosis in patients with endometrioid adenocarcinoma. Eur J Gynaecol Oncol. 2011; 32(2): 182–184.
  26. Aslan K, Sarı ME, Yalçın HR, et al. Coexistence of uterine adenomyosis is not associated with a better prognosis in endometrioid-type endometrial cancer. Ir J Med Sci. 2020; 189(3): 835–842.
  27. Chao X, Wu M, Ma S, et al. The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study. Sci Rep. 2020; 10(1): 5984.
  28. Raffone A, Seracchioli R, Raimondo D, et al. Prevalence of adenomyosis in endometrial cancer patients: a systematic review and meta-analysis. Arch Gynecol Obstet. 2021; 303(1): 47–53.
  29. Koshiyama M, Suzuki A, Ozawa M, et al. Adenocarcinomas arising from uterine adenomyosis: a report of four cases. Int J Gynecol Pathol. 2002; 21(3): 239–245.
  30. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30.
  31. Shen F, Liu Y, Lin L, et al. Association of benign gynaecological diseases and risk of endometrial and ovarian cancers. J Cancer. 2020; 11(11): 3186–3191.
  32. Hever A, Roth RB, Hevezi PA, et al. Molecular characterization of human adenomyosis. Mol Hum Reprod. 2006; 12(12): 737–748.
  33. Hu H, Li H, He Y. MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis. Exp Ther Med. 2017; 14(4): 3805–3811.
  34. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000; 92(11): 924–930.
  35. Rafnar T, Gunnarsson B, Stefansson OA, et al. Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits. Nat Commun. 2018; 9(1): 3636.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl